Retatrutide not working? Stalls, slow responders and the plateau

Reviewed 11 sourcesPublished by PepVault

Retatrutide not working? What the trials show: the climb to the top dose, how many people barely responded, why diabetes slows loss, and what a plateau is.

A woman in a cobalt sports top running up stone steps in a park
Last reviewed
Sources
11
Questions
6
Compounds
2

The short answer

First check the climb: in the phase 3 trials the top dose arrived only at week 17, and each new step takes about a month to settle. Then judge weekly averages over 12 weeks, not single days. In phase 2, the trial estimated all of the 12 mg group lost 5% or more by week 48 on the drug. Loss that slows after months is the plateau all treatments reach.

Every number checked at its primary source · · 11 sources · How we research

Evidence: Randomised phase 2 and phase 3 trials in people, published in NEJM and The Lancet, with responder shares from the phase 2 results record and some figures from Lilly's releases; plateau physiology from a modelling study and a tirzepatide post-hoc analysis. Retatrutide is investigational and not approved.

A woman in a cobalt sports top running up stone steps in a park

Is retatrutide not working, or is it too early?

Most early stalls are the dose climb. In the phase 3 TRIUMPH trials, everyone started at 2 mg once weekly and stepped up every four weeks, through 4, 6 and 9 mg, so the 12 mg group reached its dose only at the start of week 1746. The weeks before that are lower doses, and lower doses lose less. In phase 2, people on a fixed 1 mg had lost 8.7% at 48 weeks, against 24.2% on 12 mg1.

Each step also takes time to take full effect. Retatrutide's half-life, the time the body takes to clear half of a dose, is about six days in people7. A drug reaches its steady state, the level where each weekly dose replaces what was cleared, after roughly four to five half-lives: about a month. So a new step keeps building for weeks after it starts, which the chart shows. The guide Retatrutide dosage: the trial step-ups walks through each one.

Try it

How Retatrutide builds up

An estimate from a half-life of about 6.3 days, one dose a week for four weeks. The shape of the level, not a measurement.

Try your own scheduleRetatrutide in the library

Retatrutide is investigational and not approved. The schedules here describe what the trials studied, set and monitored by trial clinicians, not a dose for any one person; a dose change is a call for a clinician.

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

PepVault's dose log keeps each shot with its date and amount, so a stall can be matched to the step it followed.

Download on the App Store

7 days free on the yearly plan for new subscribers.

How many people barely lost weight in the trials?

Very few on the higher doses. The phase 2 trial counted how many people in each group reached three marks by week 48, counting only data from while people stayed on treatment, and gives each share as an estimate from its statistical model2. Every group on 8 or 12 mg was estimated at 100% at the first mark, a loss of at least 5%.

Phase 2 group (start dose)Lost 5% or moreLost 10% or moreLost 15% or more
Placebo27%9%2%
1 mg64%27%16%
4 mg (from 2 mg)87%73%55%
4 mg (from 4 mg)97%76%64%
8 mg (from 2 mg)100%90%73%
8 mg (from 4 mg)100%91%77%
12 mg (from 2 mg)100%93%83%
One hundred figures for the phase 2 12 mg group: 83 lost 15% or more, 10 lost 10 to 15%, 7 lost 5 to 10%, and none under 5%
By the trial's estimate, everyone on 12 mg crossed 5% while on the drug, but about one in six stayed under 15%: slow responders exist even at the top dose.

Two things stand out. A true non-responder, someone who lost under 5% while staying on the drug, showed up in the lower-dose groups; the estimate put none at 8 or 12 mg. And slow responders were there even at the top: about 17% of the 12 mg group (100 minus 83) finished between 5% and 15%, while others lost far more. In the 80-week phase 3 trial, had everyone stayed on 12 mg, 45.3% would have lost 30% or more4. The average hides a wide spread, so one person's pace says little about how the drug works in general.

The shares are model estimates at week 48, on treatment, and the groups were small, 33 to 69 people each. Placebo's 27% shows that some people reach a 5% loss without the drug.

Why do the headline numbers look bigger than my result?

Because the trials count in different ways, and Lilly's releases lead with the kindest one. Lilly's efficacy estimand asks what would have happened had everyone stayed on the drug; the treatment-regimen estimand counts everyone who was randomised, including people who stopped4. A placebo-adjusted figure subtracts what the placebo group lost over the same weeks35.

12 mg at 80 weeksEveryone countedHad all stayed onBeyond placebo
TRIUMPH-1, without diabetes25.0%28.3%21.0 points
TRIUMPH-2, with type 2 diabetes18.8%20.8%13.8 points

Every figure is an average change from starting weight3456. Placebo groups lost 3.9% and 5.1% when everyone was counted35. The 25% people quote is the middle of a wide spread on the top dose after 80 weeks, not a marker anyone should be on track for at week 12.

Does type 2 diabetes slow weight loss on retatrutide?

Yes. TRIUMPH-1 and TRIUMPH-2 ran the same 80 weeks on the same doses, and the group with type 2 diabetes lost less at each one: 11.9%, 16.8% and 18.8% on 4, 9 and 12 mg, against 17.6%, 23.7% and 25.0% without diabetes35. Loss was still large: had everyone stayed on 12 mg, 67.0% of people with diabetes would have lost at least 15%6.

Phase 2 pointed the same way: its diabetes trial reached 16.9% on 12 mg at 36 weeks, below the 17.5% the obesity trial had reached by week 24111. Someone with diabetes who compares their pace with the obesity trials' headline is comparing against a different group.

What is a weight-loss plateau?

A plateau is the new steady weight that every obesity treatment reaches in the end9. As weight falls, appetite pushes back: in a preliminary model of the body's energy balance by Kevin Hall at the US National Institutes of Health, it rises by roughly 80 to 100 kcal a day for each kilogram lost, until eating meets the body's smaller energy needs9. Diets hit that point within about 12 months. In the same model, semaglutide and tirzepatide weaken the pushback by roughly 40 to 70%, so the average weight keeps falling for about two years9.

For tirzepatide there is a measured answer. A post-hoc analysis of SURMOUNT-1, in people who stayed on it and lost at least 5%, defined a plateau as less than 5% change over 12 weeks and every 12 weeks after, a loose bar that still counts slow loss. The median time to reach one was 24 to 36 weeks, depending on starting BMI, and about 88 to 90% had plateaued by week 7210. People on 10 or 15 mg plateaued later.

Phase 2 average weight change on 12 mg: down 17.5% at week 24 and 24.2% at week 48, the second 24 weeks drawn lighter; a fixed 1 mg dose had lost 8.7% at week 48
Look at the slope, not the end: on 12 mg the second 24 weeks brought 6.7 points, under half the pace of the first (17.5), and the line was still falling.

Retatrutide has no published analysis like it yet. In phase 2, the 12 mg group lost 17.5% in the first 24 weeks and 6.7 points more in the next 241: the pace was slowing, and by the tirzepatide bar that average pace would count as a plateau, yet the trial's first author, Ania Jastreboff, said people 'had not yet reached a weight plateau' at week 488. In TRIUMPH-1's 104-week extension, for people who started at a BMI of 35 or more and finished 80 weeks on the drug, those who began on 12 mg averaged 30.3%, had everyone stayed on4. Retatrutide week by week lines that pace up with each dose step.

How do you tell a stall from a plateau?

  1. Write down the date each dose step began. A stall in the four weeks after a step can simply be the new level still building.
  2. Weigh yourself at the same time each morning, after the toilet and before eating, three or more days a week.
  3. Average each week's weigh-ins and compare the averages, never one day against the next.
  4. Measure your waist the same way once a month, at the navel, since it can move while the scale holds.
  5. Compare the latest 12 weeks with the 12 before. Loss that slows after months of falling is the plateau pattern; little loss from the start, at a steady dose, is the less common case.
An illustration of one month of daily weigh-ins as dots jumping up and down, with the weekly average as a calm line descending through them
The dots are noise; the line is the answer. Compare the line week to week.

PepVault's dose log keeps each shot with its date and amount, so a stall can be matched to the step it followed. Log it in PepVault

Its weight log charts every weigh-in over time, and body check-ins add your waist. Track your weight in PepVault

Commonly reported: the scale holding still for a week or two after a step-up, then dropping; weight coming off in steps rather than a smooth line; appetite creeping back in the last day or two before the next shot; and the waist shrinking during weeks when the scale barely moves.

When to get help If the weekly average has not moved for 12 weeks at a steady dose, or eating enough has become hard, take your log to a clinician, who can look at the dose and the other things that hold weight up.

Track it in the app

Sources

  1. Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 2023. PubMed 37366315
  2. ClinicalTrials.gov NCT04881760. A study of LY3437943 in participants who have obesity or are overweight (phase 2; sponsor Eli Lilly and Company). Results record. clinicaltrials.gov
  3. Jastreboff AM et al.; TRIUMPH-1 Investigators. Retatrutide, a triple hormone receptor agonist, for treatment of obesity. N Engl J Med. 2026. PubMed 42814954
  4. Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial. Press release, May 21, 2026. prnewswire.com
  5. Bellido V et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026. PubMed 42810372
  6. Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes. Press release, Sept 29, 2026. prnewswire.com
  7. Urva S et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022. PubMed 36354040
  8. Eli Lilly and Company. Lilly's phase 2 retatrutide results published in The New England Journal of Medicine show the investigational molecule achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity and overweight. Press release, June 26, 2023. prnewswire.com
  9. Hall KD. Physiology of the weight-loss plateau in response to diet restriction, GLP-1 receptor agonism, and bariatric surgery. Obesity (Silver Spring). 2024. PubMed 38644683
  10. Horn DB et al. Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials. Clin Obes. 2025. PubMed 39800653
  11. Rosenstock J et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023. PubMed 37385280

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo